kisspeptin-10 vs pt-141

updated October 28, 2026

kisspeptin-10 (tier B) vs pt-141 (tier A): what each is, why each got its grade, half-life and source counts side by side.

kisspeptin-10 · tier B

kisspeptin-family pharmacology with real HSDD and fertility signals. the strongest human trials used kisspeptin-54, not the KP-10 vial market.

tier rationale

B-tier because the clinical research around the kisspeptin pathway is real and rigorous but the regulatory pipeline is still early, and because KP-10 is not the exact molecule used in the strongest HSDD and IVF trials. Imperial College trials give drug-grade evidence at small scale, published in JAMA Network Open, for a clinically meaningful condition. Held back from A by the absence of phase 3 data, no FDA filing pending, and the molecule-identity gap between KP-54 trials and KP-10 market supply.

pt-141 · tier A

the FDA-approved sex peptide for acquired generalized HSDD in premenopausal women. off-label male use is a separate evidence lane.

tier rationale

FDA-approved for premenopausal women with HSDD as Vyleesi since June 2019. mechanism, central melanocortin MC4R agonism, targets a completely different pathway from PDE5 inhibitors like sildenafil. unlike most peptides on this list, PT-141 has a completed phase III program (RECONNECT 1 + 2, 1,267 women randomised) and an active FDA approval. widely used off-label for male sexual dysfunction, especially PDE5-inhibitor non-responders. A-tier because FDA-approved for a specific indication but the broader use case most people encounter is off-label, and effect sizes in the approved indication have been legitimately questioned by researchers.

at a glance

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.